2,4-Difluorobenzylamine (CAS: 72235-52-0) is a fluorinated aromatic amine with the molecular formula C7H7F2N. Its structure features two fluorine atoms at the 2 and 4 positions of the benzene ring attached to a benzylamine group, granting unique chemical properties that make it highly valuable in drug development. As a highly specialized pharmaceutical intermediate, 2,4-difluorobenzylamine serves almost exclusively as a critical building block in the synthesis of high-value pharmaceuticals, particularly integrase strand transfer inhibitors (INSTIs) used in HIV treatment. The presence of fluorine substituents enhances biological activity and selectivity of drug molecules, making this compound indispensable in modern medicinal chemistry. Its production typically involves the catalytic hydrogenation of 2,4-difluorobenzonitrile or nucleophilic substitution of 2,4-difluorobenzyl chloride with ammonia. Market demand is closely tied to the global HIV treatment landscape and the expansion of generic pharmaceutical manufacturing. Based on its chemical characteristics and industrial chain position, this article systematically analyzes international market dynamics of 2,4-difluorobenzylamine, focusing on core application scenarios, competitive landscape, regional differences, regulatory trends, and future outlook, providing strategic references for industry participants.
Core Application Fields and Demand
Market demand for 2,4-difluorobenzylamine is highly concentrated in pharmaceutical synthesis (≈90% of global consumption), agrochemical production (≈5%), and specialty fine chemicals including material science and analytical chemistry (≈5%). Its role as a key intermediate in HIV drug synthesis drives the vast majority of demand.
In the pharmaceutical sector, 2,4-difluorobenzylamine is an essential intermediate in the synthesis of two blockbuster HIV integrase inhibitors. Dolutegravir uses DFBA as an essential intermediate in its complex synthesis pathway, forming a critical component of highly effective single-pill regimens such as Triumeq and Tivicay. Dolutegravir is widely adopted as a first-line treatment for HIV globally due to its high efficacy, favorable side-effect profile, and relatively low potential for drug resistance, generating sustained, large-volume demand. Cabotegravir, an innovative INSTI notable for its development as a long-acting injectable formulation (Apretude, Vocabria), is used for both HIV prevention (PrEP) and treatment. The introduction of long-acting injectable regimens represents a significant technological shift in HIV management, and as global adoption grows, it is expected to provide a new, accelerating source of demand for DFBA. The compound is also used in the synthesis of antifungal agents, kinase inhibitors, and other antiviral medications including HIV reverse transcriptase inhibitors.
In agrochemical production, 2,4-difluorobenzylamine finds applications as a precursor for herbicides and pesticides, contributing to the formulation of more effective and environmentally friendly crop protection agents. Its high fluorine content enhances bioactivity and stability under diverse conditions. Additionally, the compound serves as a derivatizing agent in analytical methods, enhancing detection and quantification of various compounds in complex mixtures, and is used in the formulation of advanced materials, particularly in coatings and polymers where its properties can improve durability and resistance.
Major Market Participants
The global supply system for 2,4-difluorobenzylamine (CAS: 72235-52-0) features a pattern of “specialized fluorochemical manufacturers, primarily in China and India, dominating large-scale production, with European and Japanese companies focusing on high-purity research grades.” The market is a prime example of a niche chemical sector driven entirely by the highly regulated and rapidly growing global pharmaceutical industry. Production requires advanced catalytic hydrogenation capabilities and strict quality control to meet stringent purity standards, as slight impurities can render the final API ineffective or unsafe.
Regional Market Dynamics
Global demand for 2,4-difluorobenzylamine shows regional differentiation: “Asia-Pacific dominates production and consumption (over 70%), North America and Europe focus on high-purity research and branded pharmaceutical supply, and Latin America & Middle East/Africa follow as emerging generic manufacturing hubs.” The global market size was valued at USD 65.4 million in 2024 and is projected to grow from USD 70.8 million in 2025 to USD 122.5 million by 2032, exhibiting a CAGR of 7.2%.
Asia-Pacific currently dominates production, with China and India leading capacity expansion. India is rapidly emerging as a major producer, with Anupam Rasayan and Navin Fluorine expanding their capacities. The region’s cost advantages and established supply chains to global generic drug manufacturers make it the primary sourcing destination for DFBA. Domestic consumption in China and India is driven by local API manufacturing for HIV treatments and generic antiretroviral production for domestic and export markets.
North America and Europe account for approximately 20-25% of global demand, focused on high-purity (≥99%, low impurity profile) material for innovative drug development, branded pharmaceutical manufacturing, and research applications. The US and European pharmaceutical hubs source from specialized suppliers with full regulatory documentation. Price sensitivity is lower, but compliance requirements are stringent. These regions also host the primary demand for DFBA in long-acting injectable formulations like Cabotegravir, which require ultra-high-purity intermediates.
Latin America and Middle East/Africa are smaller but growing markets, with demand tied to local generic antiretroviral manufacturing under public health programs. Price sensitivity is high, and these regions primarily import from Asian suppliers. Brazil and South Africa have established HIV treatment programs that drive intermediate procurement.
Regulatory and Environmental Considerations
As a pharmaceutical intermediate, 2,4-difluorobenzylamine (CAS: 72235-52-0) is not a final drug substance, but its production and trade are subject to chemical control regulations and, when intended for pharmaceutical use, to GMP guidelines. The compound is classified as corrosive (C), with hazard statements H314 (causes severe skin burns and eye damage). It has risk phrase R34 (causes burns) and safety phrases S26-S27-S36/37/39-S45.
In the EU, 2,4-difluorobenzylamine is registered under REACH as an industrial intermediate. Suppliers must provide extended Safety Data Sheets (SDS) and conduct exposure assessments. The compound is not classified as a Substance of Very High Concern (SVHC) based on current data. For use as a pharmaceutical intermediate, importers must comply with EU GMP guidelines. In the US, the EPA regulates it under TSCA as an existing substance. For pharmaceutical use, manufacturers must follow FDA guidance on intermediates under 21 CFR Parts 210 and 211 (cGMP). No specific FDA registration is required for the intermediate itself, but documentation of quality and purity is expected in API DMFs.
In China, 2,4-difluorobenzylamine is listed in the “Inventory of Existing Chemical Substances” and is subject to environmental and safety regulations. Producers require a chemical production license and must comply with GB/T standards for product purity. For export to regulated markets, Chinese manufacturers obtain DMF filings and undergo customer audits. In India, it is regulated under the Drugs and Cosmetics Act when used as a drug intermediate, and under hazardous chemical rules for safety.
Environmentally, the catalytic hydrogenation process used in production generates waste catalysts and requires careful management. Green chemistry initiatives focus on recyclable catalysts and continuous-flow hydrogenation to reduce waste. The compound is classified as slightly hazardous to water (WGK Germany 3) and should not be allowed to enter groundwater, waterways, or sewage systems undiluted.
Future Outlook
The market outlook for 2,4-difluorobenzylamine is tied to three drivers: sustained demand for HIV antiretroviral drugs, the transition to long-acting injectable formulations, and the expansion of generic pharmaceutical manufacturing. The global market is expected to grow at a CAGR of 7.2% through 2032.
On the demand side, first, with an estimated 39 million people living with HIV worldwide, the need for effective treatments remains critical. WHO recommendations for Dolutegravir-based treatments as first-line therapy continue to accelerate demand. Second, the adoption of long-acting injectables like Cabotegravir for PrEP and treatment represents a significant growth avenue, as these formulations require high-purity intermediates to maintain efficacy and safety standards. Third, patent expiries and the push toward generic versions of HIV drugs will expand production volumes, increasing demand for cost-effective intermediates.
Challenges include: raw material price volatility (2,4-difluorobenzonitrile), stringent purity requirements that limit the number of capable producers, and potential substitution by alternative synthetic routes or new drug classes. The market‘s heavy dependence on specific HIV drugs makes it sensitive to regulatory approvals, patent expirations, and changes in global health policies. Enterprises should focus on securing regulatory filings (DMF, CEP), investing in green hydrogenation technologies, and developing derivative products to capture higher value across the pharmaceutical intermediate value chain.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals and pharmaceutical intermediates, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the pharmaceutical and fine chemical industries. Relying on core technological advantages in fluorinated intermediate synthesis and purification, we provide high-purity 2,4-Difluorobenzylamine (CAS: 72235-52-0) to global customers. Our product is manufactured under strict quality management systems, fully complying with pharmaceutical intermediate standards. It is an ideal building block for HIV integrase inhibitor synthesis, agrochemical development, and specialty chemical applications.
1. Technical Advantages
- High Purity: Our 2,4-difluorobenzylamine achieves purity ≥99% (GC) with pharmaceutical grade, and ≥98% for industrial grade, meeting stringent API intermediate requirements.
- Low Impurity Profile: Strict control of residual solvents (meets ICH Q3C guidelines), heavy metals (≤10 ppm), and moisture (≤0.5%).
- Batch Consistency: Batch-to-batch variation controlled within 0.2% for key indices.
2. Product Advantages
- High Fluorine Content (26.5-27.5%): Enhances bioactivity and metabolic stability of target drug molecules.
- Excellent Stability: Maintains stability under diverse reaction conditions, suitable for complex synthetic workflows.
- Flexible Packaging: 25KG HDPE drums with nitrogen blanket (industrial), 5KG/1KG aluminum bottles (R&D), custom packaging upon request.
- Reliable Supply Chain: Annual capacity 100-200 tons, with dedicated inert atmosphere storage (2-8°C, under argon/nitrogen).
3. Application Fields
- Pharmaceutical Intermediates: HIV integrase inhibitors (Dolutegravir, Cabotegravir), antifungal agents, kinase inhibitors, antiviral drugs.
- Agrochemical Production: Herbicide precursors, pesticide intermediates, environmentally friendly crop protection agents.
- Specialty Chemicals: Advanced polymer modification, analytical derivatizing agent, material science research.
4. Service Support
Our technical team provides impurity profiling, custom synthesis, and regulatory support (DMF preparation, customer audits, REACH/TSCA compliance). We offer just-in-time delivery and competitive pricing for both research quantities and bulk orders.
5. Why Choose XinChem
- Professionalism: 20+ years in chemical and pharmaceutical intermediates.
- Flexibility: Tailored to customer purity and packaging requirements.
- Cost-effectiveness: High quality at competitive prices.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Apr-13-2026